Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient

The composition for the use as claimed in any of the preceding claims, characterized in that the sulfoalkyl ether β-cyclodextrin is a sulfobutyl ether β-cyclodextrin or a sulfoethyl ether β-cyclodextrin.

The composition for the use as claimed in any of the preceding claims, characterized in that the degree of substitution of the cyclodextrin with sulfoalkyl ether groups is from 3 to 8, preferably from 4 to 8, more preferably from 5 to 8, more preferably from 6 to 7.

The composition for the use as claimed in any of the preceding claims, characterized in that the composition comprises a therapeutically effective amount of the complex composed of delphinidin and sulfoalkyl ether β-cyclodextrin.

The composition for the use as claimed in any of the preceding claims, characterized in that the composition is used as a monopreparation.

The composition for the use as claimed in any of the preceding claims, further comprising one or more pharmaceutical excipients and/or additives, preferably selected from the group consisting of a pharmaceutically acceptable carrier, fillers, odorants and stabilizers.

The composition for the use as claimed in any of the preceding claims in a formulation form for administration in a form selected from the group consisting of oral, rectal, parenteral, including intraperitoneal, percutaneous, subcutaneous, intramuscular, intravenous, ophthalmic, pulmonal and nasal.

The composition for the use as claimed in any of the preceding claims, characterized in that the complex composed of delphinidin and the sulfoalkyl ether β-cyclodextrin is used in a pharmaceutical preparation for the controlled and/or delayed release of the delphinidin.

A pharmaceutical composition comprising a complex composed of delphinidin and a sulfoalkyl ether β-cyclodextrin.